阿尔茨海默病中的生物标志物：血小板、血红蛋白和维生素B12的评估
Biomarkers in Alzheimer's disease: Evaluation of platelets, hemoglobin and vitamin B12.
作者信息
Dos Santos Gustavo Alves Andrade, Pardi Paulo Celso
机构信息
Universidade de São Paulo - USP. Faculdade de Medicina de Ribeirão Preto. Departamento de Anatomia e Cirurgia. Ribeirão Preto, SP, Brazil.
Centro Universitário do Senac - Unidade Tiradentes. Departamento de Pós-graduação em Farmácia.
出版信息
Dement Neuropsychol. 2020 Jan-Mar;14(1):35-40. doi: 10.1590/1980-57642020dn14-010006.
UNLABELLED
Currently, the most likely hypotheses as the cause of Alzheimer's disease are deposition of amyloid beta peptide in the cerebral cortex and hyperphosphorylation of Tau protein. The diagnosis of Alzheimer's disease is based on the exclusion of other diseases, behavioral assessments, and blood and imaging tests. Biotechnology has created interesting perspectives for the early detection of Alzheimer's disease through blood analysis, with special attention to platelets, hemoglobin and vitamin B12.
OBJECTIVE
To evaluate the concentrations of platelets, hemoglobin and vitamin B12 in the blood of older adults with and without dementia of Alzheimer's disease.
METHODS
A case-control study involving 120 individuals was conducted, seeking to establish a correlation between changes in platelet, hemoglobin and vitamin B12 concentrations in patients with confirmed AD and in individuals in the inclusion group without AD. The study met the established ethical requirements.
RESULTS
Hemoglobin and platelet levels were statistically lower in patients with AD. The biochemical evaluation in AD patient and healthy groups for vitamin B12 showed a decrease in the levels of this compound in patients with AD.
CONCLUSION
We demonstrated the feasibility of the use of blood biomarkers as predictive markers for the diagnosis of AD.
未标注
目前，作为阿尔茨海默病病因最有可能的假说是β-淀粉样肽在大脑皮层的沉积以及 Tau 蛋白的过度磷酸化。阿尔茨海默病的诊断基于排除其他疾病、行为评估以及血液和影像学检查。生物技术通过血液分析为阿尔茨海默病的早期检测创造了有趣的前景，尤其关注血小板、血红蛋白和维生素 B12。
目的
评估患有和未患有阿尔茨海默病痴呆症的老年人血液中血小板、血红蛋白和维生素 B12 的浓度。
方法
进行了一项涉及 120 人的病例对照研究，旨在确定确诊为 AD 的患者以及纳入组中未患 AD 的个体的血小板、血红蛋白和维生素 B12 浓度变化之间的相关性。该研究符合既定的伦理要求。
结果
AD 患者的血红蛋白和血小板水平在统计学上较低。AD 患者组和健康组对维生素 B12 的生化评估显示，AD 患者中该化合物的水平降低。
结论
我们证明了使用血液生物标志物作为 AD 诊断预测标志物的可行性。
Zotero 插件